1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
A-SPINE Asia Co., Ltd.

A-SPINE Asia Co., Ltd.

TTPEX:6758
30.70
TWD
-0.20
(-0.65%)
404.13MMarket Cap
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
27.25
33.04
31.79
31.99
27.46
22.99
24.51
29.04
30.06
33.32
- -
Basic EPS, GAAP
3.5
4.77
3.98
4.2
2.26
1.32
0.59
0.68
0.62
1.12
- -
Free Cash Flow per Basic Share
0.29
-7.44
2.29
1.73
2.01
2.38
1.01
0.04
0.97
2.09
- -
Dividend per Share
3.28
3.28
3.25
2.4
2.5
2
1.5
1
1
1
- -
Book Value per Share
15.6
16.97
20.7
22.44
22.16
21.47
20.57
20.34
20.1
20.37
19.62
Tangible Book Value per Share
15.53
16.94
20.7
22.35
22.04
21.36
20.39
20.18
19.81
20.11
19.38
Basic Weighted Avg Shares
12
12
13
13
13
13
13
13
13
13
13
Sales/Revenue/Turnover
340
412
400
431
370
310
330
391
405
449
- -
Operating Margin (%)
15.11
17.6
15.68
16.72
8.93
6.74
2.39
2.84
1.93
4.11
- -
Depreciation Expense
4
6
8
9
13
16
16
16
13
13
- -
Net Income, GAAP
44
59
50
57
30
18
8
9
8
15
- -
Effective Tax Rate (%)
17.77
19.85
21.71
20.03
11.54
17.01
19.99
21.01
20.03
19.94
- -
Profit Margin (%)
12.85
14.42
12.52
13.12
8.21
5.73
2.43
2.35
2.08
3.36
- -
Working Capital
187
164
201
183
163
164
152
144
164
138
123
LT Debt
- -
93
86
86
67
64
56
48
66
33
47
Total Equity
210
229
279
302
299
289
277
274
271
274
264
Return on Invested Capital (%)
- -
20.62
13.41
14.24
6.72
4.05
1.46
1.76
1.74
3.77
- -
Return on Capital (%)
- -
21.6
14.38
14.63
7.52
4.53
2.26
2.7
2.66
4.33
- -
Return on Common Equity (%)
- -
27.09
19.75
19.47
10.12
6.04
2.83
3.34
3.09
5.53
- -

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
96
97
113
LT Borrowings
53
33
30
LT Finance Leases
- -
- -
17
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
13
13
13
Market Capitalization
505
532
404

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
361
349
370
Cash, Cash Equivalents & STI
67
57
62
Accounts Receivable, Net
91
80
93
Inventories
193
204
204
Total Current Liabilities
215
211
246
Payables & Accruals
- -
- -
- -
ST Debt
96
97
113
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-1.65%
1.33%
Free Cash Flow
- -
511.42%
116.15%
Net Income, GAAP
- -
-2.17%
79.3%
Sales/Revenue/Turnover
- -
4.63%
10.83%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
405
2025
- -
- -
449
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.62
2025
- -
- -
1.12
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1
2025
- -
- -
1
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Hao Juan Xue
Full Time Employees
69
Sector
Health technology
Industry
Medical specialties
Address
No. 80, Chenggong Road New Taipei TP Taiwan 234
IPO Date
Jan 2, 2020
Website
aspine.com.tw
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
A-SPINE Asia Co., Ltd. (6758.TWO) engages in the research, development, manufacture, and marketing of spinal implants and instruments primarily for orthopedic surgery; its core products include spinal fixation systems such as cervical anterior fixation (e.g., CervoLoc, WinLoc II), thoracic and lumbar fixation systems (e.g., SmartLoc, SmartMIS, PACH); interbody fixation systems comprising ACDF cages, PLIF/TLIF cages, and ALIF lumbar cages; balloon kyphoplasty products like Avalon vertebral expander; and vertebral body replacement products such as A-Mesh titanium mesh; the company also sells imported orthopedic medical devices as an agent and accepts ODM/OEM orders from brands in Germany and Australia. Founded in 2001 and headquartered at 20F, No. 80, Section 1, Chenggong Road, Yonghe District, New Taipei City, Taiwan, A-SPINE operates in over 15 countries including Taiwan, China, the Philippines, Australia, New Zealand, Iran, Vietnam, Indonesia, Spain, Trinidad, and Sri Lanka, targeting surgeons and medical centers focused on cervical, thoracolumbar, and minimally invasive endoscopic spine applications. The company maintains ISO 13485 quality certification, EU CE (MDD) marking, and pursues MDR compliance while emphasizing clinical feedback from Taiwanese and international orthopedic experts; no major acquisitions, funding rounds, partnerships, or product launches have been publicly reported in the last 1-2 years, with steady focus on expanding global sales and product reliability through evidence-based improvements.